n the active ingredient : Pirenoxine
is a preparation of 1-hydroxy-5-oxo-5H-pyrido(3,2-α)-phenoxazine-3-carboxylic acid, a compound having a chemical structure similar to xanthommatin, an eye pigment of the insect, with a pyridophenoxazone nucleus.
Though the pathogenesis of cataract has not yet been clearly determined, conversion of water-soluble protein in the lens to insoluble protein by quinone substances produced as the result of abnormal metabolism of aromatic amino acid, is said to be responsible for cataract according to "Quinoid Theory" established as the result of biochemical study on lens protein in the Dept. of Ophthalmology, Osaka University Medical School.
Pirenoxine is found to competitively inhibit the action of the quinone substances. Extensive experiments, both basic and clinical, have proven that this agent prevents the progress of cataract.
The solvent is isotonic, buffered solution containing 0.02% methylparaben, 0.01% propylparaben and 0.0001% thimerosal as preservatives.
Senile cataract, Diabetic cataract
Dissolve a tablet in 15 mL of the solvent. A clear yellow ophthalmic solution is obtained. Instil 1-2 drops of the prepared solution into the eye 5 times daily.
English instruction leaflet inside the box
Manufactured in Japan
Size : 15 ml /bottle